Quantcast
Home > Quotes > TRVN
TRVN

Trevena, Inc. Common Stock (TRVN) Quote & Summary Data

$0.8826
*  
0.0145
1.62%
Get TRVN Alerts
*Delayed - data as of Aug. 16, 2019  -  Find a broker to begin trading TRVN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
3.5
Today's High / Low
$ 0.8958 / $ 0.8515
Share Volume
366,779
50 Day Avg. Daily Volume
620,633
Previous Close
$ 0.8971
52 Week High / Low
$ 3.5783 / $ 0.3823
Market Cap
81,699,806
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.27
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.43

Intraday Chart

Shares Traded

Share Volume:
366,779
50 Day Avg. Daily Volume:
620,633

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.27

Trading Range

The current last sale of $0.8826 is 130.87% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.8958 $ 3.5783
 Low: $ 0.8515 $ 0.3823

Company Description (as filed with the SEC)

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS. Unless the context otherwise requires, we use the terms "Trevena," "company," "we," "us," and "our" to refer to Trevena, Inc. Using our proprietary product platform, we have identified and are developing the following product candidates: ยท Oliceridine injection: We are developing oliceridine, a G protein biased mu-opioid receptor, or MOR, ligand, for the management of moderate-to-severe acute pain in hospitals or other controlled clinical settings where intravenous, or IV, administration of opioids is warranted. We have completed two pivotal Phase 3 efficacy studies (APOLLO 1 and APOLLO 2) of oliceridine in moderate-to-severe acute pain following bunionectomy and abdominoplasty, respectively.  ... More ...  



Risk Grade

Where does TRVN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.88
Open Date:
Aug. 16, 2019
Close Price:
$ 0.8826
Close Date:
Aug. 16, 2019


Consensus Recommendation

Analyst Info